Genetics and Variable Drug Response
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Annual health care expenditures currently exceed $2.5 trillion in the United States, a cost burden equivalent to more than $8000 per person per year. Treatment strategies designed to optimize efficacy, ie, avoiding therapeutic failure while minimizing toxicity, hold the potential to reduce this cost burden. For many drugs, variability in outcome is influenced by 1 or more genetic factors. Because many of these genetic factors have only recently been challenged with modern pharmaceuticals, variants of strong clinical relevance are often found at fairly high frequency within the general population. Individualized drug therapy is especially desirable when the therapeutic index is narrow and the consequences of drug toxicity are life-threatening (eg, antineoplastics, anticoagulants, immune modulators). Many such drugs are administered at maximally tolerated doses. Because these doses are often chosen from population averages, as many as one-third of patients exposed may develop unacceptable toxicity, and a significant proportion of patients will not respond. This increases the risk-benefit ratio for individual patients and imposes a sizeable economic strain on the health care system. An important unanswered question is whether genetics will solve this problem or add further cost to health care with relatively little benefit on outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043
Cited by
A Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996–2013
Mrazek, D. A., Hornberger, J. C., Altar, C. A., & Degtiar, I. (2014) · Psychiatric Services · doi:10.1176/appi.ps.201300059 · Cited by 580
Ramsey, L. B., Johnson, S. G., Caudle, K. E., Haidar, C. E., Voora, D., Wilke, R. A., Maxwell, W. D., McLeod, H. L., Krauss, R. M., Roden, D. M., et al. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.125 · Cited by 433
Self-citationThe social and economic burden of treatment-resistant schizophrenia: a systematic literature review
Kennedy, J. L., Altar, C. A., Taylor, D. L., Degtiar, I., & Hornberger, J. C. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32836508e6 · Cited by 392
“Pharmacogenomic tests are anticipated to help guide medication selection and dosing, hasten response rates, increase compliance, and improve quality of life for patients, and thereby reduce the escalating rates in annual health expenditures (Wilke and Dolan, 2011).”
BackgroundWilke, R. A., Ramsey, L. B., Johnson, S. G., Maxwell, W. D., McLeod, H. L., Voora, D., Krauss, R. M., Roden, D. M., Feng, Q., Cooper-DeHoff, R. M., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.57 · Cited by 332
Self-citationSecondary use of clinical data: The Vanderbilt approach
Danciu, I., Cowan, J. D., Basford, M., Wang, X., Saip, A., Osgood, S., Shirey-Rice, J., Kirby, J., & Harris, P. A. (2014) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2014.02.003 · Cited by 277
Metadata
- Authors
- Wilke, R. A., & Dolan, M. E.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2011-07-20
- Volume
- 306
- Issue
- 3
- Pages
- 306-7
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2050273326
- Cited by
- 56
- References
- 1
- FWCI
- 10.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genetics and Variable Drug Response. https://app.cochat.ai/papers/10.1001/jama.2011.998
- The paper
- Wilke, R. A., & Dolan, M. E. (2011). Genetics and Variable Drug Response. JAMA. https://doi.org/10.1001/jama.2011.998
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.